JGJames Christopher Gates

James Christopher Gates

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Christopher Gates has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting Oral Cancer From Precursor Lesions: The Case for a Standardized Framework of Analysis to Improve Prediction Modeling

    by Michael E. Troka, James C. Gates

    Oral Cancer often occurs from the transformation of precursor lesions, and this offers an opportunity for early detection. Current methods to assess risk of precursor lesion progression to oral cancer incompletely predict risk. A multimodal framework that leverages machine learning is needed to improve prediction. In this manuscript, we propose more standardization in the study of OPMD across sites and propose a framework aligned to the principles of the NCI's Human Tissue Atlas Network (HTAN). We explore whole exome sequencing for genomic risk, methylation array for environmental genetic regulation, RNA sequencing for transcriptional control of cellular programs with spatial transcriptomics to fulfill the spatial requirements of HTAN. Moreover, we propose a machine learning (ML) analysis whereby a learned image‐molecular association is created by integrating H&E histology and sequencing results. Once these associations are learned, a “Teacher‐Student” model can be created whereby the Student model can be deployed to infer the “molecular associations” from H&E and patient covariates alone. Such a framework integrating multiomic data across multiple different biologic processes and time points can help to better understand and potentially even predict the biologic events that underlie oral cancer initiation.

  • Multimodal risk assessment for oral potentially malignant disorders

    by Michael E. Troka, Alessandro Villa, James C. Gates

  • Predicting Oral Cancer From Precursor Lesions: Assessing Current Methods and Future Directions

    by Michael E. Troka, James C. Gates

    PURPOSE: Oral potentially malignant disorders (OPMDs) pose a significant clinical challenge due to their potential to develop into oral squamous cell carcinoma, a prevalence of 4%-5% of the US population, and malignant transformation rates that approach 10%. Current methods to assess risk of OPMD progression to oral cancer are fraught with limitations and incompletely predict risk. METHODS: We review existing diagnostic and prognostic tools for OPMDs, examining their validation evidence, performance characteristics, and clinical utility. RESULTS: Although some tools provide rule-in or rule-out capabilities, each tool interrogates a single biological layer, and none provides comparable positive predictive value and negative predictive value in a single tool. CONCLUSION: A framework integrating multiomic data across multiple different biologic processes and time points inclusive of benign mimics is needed to better identify which lesions are true OPMDs, and which warrant escalation and intervention versus surveillance or de-escalation.

  • Open Access

    Biopsy for Suspicious Oral Lesions: A Review From the American Head and Neck Society‐Cancer Prevention Service

    by James Christopher Gates, Heather Edwards, Alessandro Villa, Nick Purdy, Michael Troka, Peter Varela, Quinn Self, Yingci Liu, Yusuf Dundar, Patricia Joyce Brooks, et al.

    Background: Oral cancer is often preceded by a precursor lesion. This presents an opportunity for early diagnosis and intervention. Method of biopsy and interpretation are not well standardized and novel methods of analysis are now being investigated. Methods: We conducted a narrative review of PubMed/MEDLINE (last search August 31, 2025), focusing on adult oral precancerous lesions evaluated in outpatient settings. Results: Incisional punch biopsy is reproducible and often provides the diagnostic information needed. However, scalpel biopsy should be considered when initial biopsy is equivocal, depth of invasion is desired, or to minimize sampling bias. Limited studies show improved sensitivity of combining saliva and plasma sampling. Targeted fluorescent imaging may aid in future biopsy site selection. AI has shown encouraging results in both automated detection of dysplasia and prediction of malignant progression, achieving performance comparable to clinically validated grading systems. Conclusion: This update serves to further inform biopsy of oral suspicious lesions and provide a framework for future investigation.


  • Open Access

    Clinical Management Update of Oral Leukoplakia: A Review From the American Head and Neck Society Cancer Prevention Service

    by James C. Gates, Marianne Abouyared, Yelizaveta Shnayder, D. Gregory Farwell, Andrew Day, Faizan Alawi, Michael Moore, Andrew J. Holcomb, Andrew Birkeland, Joel Epstein

    Background: Oral potentially malignant disorders (OPMDs) occur in up to 4%–5% of the population, of which oral leukoplakia (OL) is the most common subtype. Predicting high‐risk OL remains a challenge. Early diagnosis and effective treatment are thought to be of paramount importance to improve outcomes.Methods: We searched PubMed and Clinicaltrials.gov data for updates in the clinical management of OL from 2015 to current.Results: Recent publication of large cohorts of patients with OL aids in counseling patients regarding risk of malignant transformation. Management for OL includes surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention. Several new entities show promise regarding candidate biomarkers, chemoprevention agents, and diagnostic adjuncts, though all require further validation.Conclusion: This update serves to further inform clinical management of OL and provide impetus for future investigations.Trial Registration: NCT00099021, NCT00951379, NCT05727761, NCT05727761


  • Open Access

    Treatment Response of Gingival Squamous-Cell Carcinoma to Palliative Intent Immunotherapy

    by Natalia Trehan, Angelina Debbas, Mykaihla Sternick, Jennifer Johnson, James C. Gates

    The use of PD-1 immune checkpoint inhibitor medications has become a common practice in the treatment of recurrent and metastatic head and neck squamous-cell carcinomas. Success in this setting has led to the investigation of their efficacy in locally advanced cases as a part of first-line therapy. In this report, we detail the treatment response to palliative intent immunotherapy of three geriatric patients with mandibular gingival squamous-cell carcinoma who decided against surgical intervention. Patient #1 was treated with pembrolizumab, a PD-1 inhibitor, and displayed complete clinical and radiologic response of the gingival mass after three months of treatment, which is ongoing at 19 months from initiation. Patients #2 and 3 are each on treatment with single-agent pembrolizumab, with partial response of their tumors, minimal side effects, and ongoing response at 9 and 5 months of treatment, respectively. Durable clinical treatment response to palliative immunotherapy, as is evident in this report, warrants further consideration and investigation in the geriatric population. With appropriate patient selection, surgery may be avoided and allow patients to prioritize quality of life over curative intent surgery.


  • Open Access

    Negative pressure wound therapy for complex oral wounds

    by Mykaihla Sternick, James C Gates, Allen Champion, Andrew Yampolsky

    Negative pressure wound therapy provides a nonsurgical treatment option for many types of complex wounds. This therapy utilizes the vacuum-assisted closure device, which decreases air pressure, removes fluid that accumulates within the wound, and aids to facilitate changes that promote healing. Despite the increased use of negative pressure wound therapy in the head and neck region, there is substantially less data available on the management of transoral vacuum-assisted wound closure. Herein, we present a case of a novel approach for the creation and use of a transoral wound vac for a patient with a refractory orocutaneous wound in the setting of multiple previous free flaps and surgeries. A watertight seal was able to be maintained and the patient was compliant with treatment, resulting in successful management of the wound. We promote the consideration of this novel technique’s use for similar difficult-to-treat oral wounds.

  • Genomic profiling and precision medicine in complex ameloblastoma

    by James C. Gates, Allison P. Clark, Elliot Cherkas, Aditya V. Shreenivas, Dennis Kraus, Natalie Danzinger, Richard S. P. Huang, Jennifer Johnson, Jeffrey S. Ross

    Background: Ameloblastoma may present a significant treatment challenge in the locally advanced, recurrent and metastatic setting. Comprehensive genomic profiling (CGP) can identify targetable genomic alterations to aid in treatment.Methods: Ameloblastoma samples were sequenced using hybrid‐capture based sequencing. A systematic literature review was performed to examine outcomes in studies employing targeted treatment in ameloblastoma.Results: We reviewed 14 cases of Ameloblastoma using CGP. There were six patients with activating BRAF mutations, five with PIK3CA, five with SMO, four with FGFR2, one with EGFR, and one with ROS1. All cases were MSI stable and the median TMB was 2.5 mutations/Mb. A separate literature review of clinical outcomes in ameloblastoma showed a predominance of at least partial response to targeted treatment (7/12 cases).Conclusion: CGP is helpful in identifying specific driver mutations in patients with complex ameloblastoma. Targeted treatment has been employed with success in achieving treatment response.


  • Open Access

    Surgical ciliated cyst of the maxillofacial region: a systematic review

    by James C. Gates, Daniel I. Taub, Elliot Cherkas, Madalina Tuluc, Lionel Gold

    Background: The surgical ciliated cyst of the maxilla was initially reported as a sequela of Caldwell–Luc type open maxillary sinus procedures. Recently, other etiologies have become apparent and cases have been reported outside of the maxilla. They have the potential for local destruction and at times may mimic a locally aggressive tumor or cyst. We aim to elucidate the etiopathogenesis of the surgical ciliated cyst to improve prevention, diagnosis and treatment of these lesions.Body: A systematic review of the literature using PubMed and Scopus databases was conducted to assess the presentation, treatment, and outcomes of this disease. Surgical ciliated cysts of the maxillofacial region shows a 1.1:1 female-to-male ratio with a protracted time to diagnosis (range: 4–22 years). Typically, radiology shows a unilocular radiolucency (95%) and histology predominantly shows pseudostratified ciliated columnar epithelium (58%). The most common treatment of these lesions involves enucleation and curettage. In rare instances, transfacial approaches, resection, and reconstruction are required. Recurrence ranges from 6 to 20%.Conclusion: Surgical ciliated cyst should be considered in a patient presenting with an orofacial mass or edema who has a history of maxillofacial injury or surgery. Timely diagnosis will decrease the severity and morbidity associated with this entity. Meticulous surgical technique can aid in the prevention of this lesion.